Belimumab for lung scarring in autoimmune disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a connective tissue disease like rheumatoid arthritis, lupus, or myositis with lung scarring (ILD).
- Your lung disease is still active or getting worse despite standard treatments.
- You are not on continuous oxygen, and your lung function is not severely low.
- You are not pregnant, and if you could become pregnant, you agree to use highly effective birth control.
- You are willing to give yourself (or have a caregiver give) the study drug as a shot under the skin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Lung Diseases, Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.